New hope for nose cancer patients: combo therapy targets recurrence
NCT ID NCT07331428
First seen Jan 09, 2026 · Last updated May 16, 2026 · Updated 12 times
Summary
This study tests a two-step treatment for people whose nasopharyngeal cancer has come back in the same area. First, patients get a targeted drug (MRG003) plus an immunotherapy (PD-1) for six weeks. Then they switch to a chemotherapy pill (capecitabine) plus the same immunotherapy for up to a year. The goal is to see if this approach shrinks tumors and delays further growth. The trial involves 25 adults aged 18-70 whose cancer returned more than a year after initial treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.